Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer

Bristol-Myers Squibb Company  BMYannounced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application (sBLA) for the label expansion of Opdivo (nivolumab) to treat patients with small cell lung cancer (“SCLC”) whose disease has progressed after two or more prior lines of therapy.

 The FDA set an action date of Aug 16, 2018.